New studies show FlexPen® superiority to SoloStar® in dose accuracy
15 May 2008
Two independent studies show that FlexPen® is more accurate when delivering insulin than other pens like the newly launched prefilled device, SoloStar®, from Sanofi-Aventis, which FlexPen® significantly outperformed in both studies 1,2.
The two studies were lead by Prof Andreas Pfützner from IKFE, Institute for Clinical Research and Development in Germany1, and Dr Toshinari Asakura from the Niigata University of Pharmacy and Applied Life Sciences in Japan2. The German study was published in the May 2008 issue of Diabetes Science and Technology1.
Read the releaseRSS Feed
The latest Novo Nordisk news are now available through Really Simple Syndication - RSS.



